---
title: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
date: '2024-07-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39018531/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240718181716&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this head-to-head clinical trial of risankizumab and
  ustekinumab involving patients with moderate-to-severe Crohn''s disease who had
  had unacceptable side effects with anti-TNF therapy or an inadequate response to
  such therapy, risankizumab was noninferior to ustekinumab with respect to clinical
  remission at week 24 and superior with respect to endoscopic remission at week 48.
  (Funded by AbbVie; ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In this head-to-head clinical trial of risankizumab and ustekinumab involving patients with moderate-to-severe Crohn's disease who had had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy, risankizumab was noninferior to ustekinumab with respect to clinical remission at week 24 and superior with respect to endoscopic remission at week 48. (Funded by AbbVie; ClinicalTrials.gov number, ...